Alkermes (ALKS) Depreciation & Amortization (CF) (2010 - 2026)
Alkermes (ALKS) reported Depreciation & Amortization (CF) of $19.4 million for Q1 2026, up 161.81% year-over-year from $7.4 million in Q1 2025, and up 405.17% quarter-over-quarter from $3.8 million in Q4 2025.
Alkermes (ALKS) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $19.4 million in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $19.4 million, up 161.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $39.2 million (up 40.42% YoY), and the FY2025 annual result was $27.2 million, down 4.79% from the prior year.
- Depreciation & Amortization (CF) improved to $19.4 million in Q1 2026 per ALKS's latest filing, from $3.8 million in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $19.7 million in Q4 2022 and troughed at $3.8 million in Q4 2025.
- A 5-year average of $13.4 million and a median of $18.5 million in 2023 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2024 and 2026: Depreciation & Amortization (CF) slumped 64.98% in 2024, then soared 161.81% in 2026.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $19.7 million in 2022, then slipped by 5.77% to $18.5 million in 2023, then sank by 63.07% to $6.8 million in 2024, then slumped by 43.83% to $3.8 million in 2025, then soared by 405.17% to $19.4 million in 2026.
- Business Quant data shows ALKS's Depreciation & Amortization (CF) at $19.4 million in Q1 2026, $3.8 million in Q4 2025, and $8.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 239.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 119.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 22.60 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 7.20 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 172.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 19.43 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 22.68 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 21.95 Mn |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | 497,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.43 Mn |
| Mar 31, 2026 | 19.43 Mn |
| Dec 31, 2025 | 3.85 Mn |
| Dec 31, 2025 | 3.85 Mn |
| Sep 30, 2025 | 8.08 Mn |
| Sep 30, 2025 | 8.08 Mn |
| Jun 30, 2025 | 7.82 Mn |
| Jun 30, 2025 | 7.82 Mn |
| Mar 31, 2025 | 7.42 Mn |
| Mar 31, 2025 | 7.42 Mn |
| Dec 31, 2024 | 6.85 Mn |
| Dec 31, 2024 | 6.85 Mn |
| Sep 30, 2024 | 6.97 Mn |
| Sep 30, 2024 | 6.97 Mn |
| Jun 30, 2024 | 6.66 Mn |
| Jun 30, 2024 | 6.66 Mn |
| Mar 31, 2024 | 8.06 Mn |
| Mar 31, 2024 | 8.06 Mn |
| Dec 31, 2023 | 18.54 Mn |
| Dec 31, 2023 | 18.54 Mn |